Last reviewed · How we verify
NCT07105475
Treatment of ADHD Using High and Low Frequency Paired Associative Deep Transcranial Magnetic Stimulation
NA trial testing Paired Associative Transcranial Magnetic Stimulation (TMS) in Attention Deficit Hyperactivity Disorder in 90 participants. Currently enrolling.
1 September 2027
Quick facts
| Lead sponsor | Ben-Gurion University of the Negev |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 90 |
| Start date | 19 July 2023 |
| Primary completion | 1 September 2027 |
| Estimated completion | 1 September 2028 |
| Sites | 1 location across Israel |
Drugs / interventions tested
- Paired Associative Transcranial Magnetic Stimulation (TMS)
Conditions studied
- Attention Deficit Hyperactivity Disorder — all drugs for Attention Deficit Hyperactivity Disorder →
- Neurodevelopmental Disorders — all drugs for Neurodevelopmental Disorders →
- Prefrontal Cortex Dysregulation — all drugs for Prefrontal Cortex Dysregulation →
- Cortical Arousal Imbalance — all drugs for Cortical Arousal Imbalance →
Sponsor
Ben-Gurion University of the Negev
Who can join
Adults 18 to 65, any sex, with Attention Deficit Hyperactivity Disorder or Neurodevelopmental Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study investigates the effects of high and low-frequency paired associative deep transcranial magnetic stimulation (dTMS) on adults with Attention Deficit Hyperactivity Disorder (ADHD). The study aims to explore whether targeting the prefrontal cortex with paired stimulation can improve symptoms of ADHD by balancing cortical arousal between the brain hemispheres. A total of 90 participants with ADHD will be recruited. Participants with ADHD will undergo three weeks of daily TMS treatment, while participants who receive a sham treatment will be included for baseline comparisons. The study will measure electrophysiological, cognitive, and clinical outcomes using a variety of assessments, including EEG, cognitive tests, and CAARS to evaluate the treatment's efficacy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07105475
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Attention Deficit Hyperactivity Disorder
Currently open trials in the same condition.
- NCT07001475 — A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperact · Phase 1 · recruiting
- NCT06847165 — Trigeminal Nerve Stimulation for Children With Prenatal Alcohol Exposure · NA · recruiting
- NCT06325813 — ADHD PreSMA Response Inhibition Therapy · NA · recruiting
- NCT06248229 — A Trial of Dyanavel XR in Treating Co-occurring Fatigue Symptoms in Adults With Attention Deficit Hyperactivity Disorder · Phase 4 · recruiting
- NCT06232226 — Attention Deficit Hyperactivity Disorder · NA · recruiting
Other Ben-Gurion University of the Negev trials
Trials by the same sponsor.
- NCT06826937 — Short-Term Recall and Reprocess Therapy for Post Traumatic Stress Disorder (PTSD) · NA · recruiting
- NCT06416475 — The Effect of Mankai on Glycemic Control Among Patients With T2D · Phase 2 · active not recruiting
- NCT07116785 — Accelerated Rotational Field Deep TMS for Treating OCD · NA · recruiting
- NCT05726890 — Examining the Effectiveness of Two Behavioral Interventions for Sleep Problems in Infants · NA · recruiting
- NCT04945109 — Wolffia Globosa (Mankai) and Glycemic Control Among Patients With Type 2 Diabetes · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07105475 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ben-Gurion University of the Negev
- Last refreshed: 6 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07105475.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing